[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100648199":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":37,"locations":18,"responsibleParty":43,"collaborators":45,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":18,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":18,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":71,"overallStatus":76,"whyStopped":18,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":18},{"fullName":5,"class":6},"University of Fujairah","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention Arm: Pharmacist-Led Prescribing Optimization","EXPERIMENTAL","Participants in this arm will receive usual dental care supplemented by a pharmacist-led intervention. A clinical pharmacist will conduct structured prescription audits, provide evidence-based feedback to dentists, apply standardized drug algorithms for oral mucosal disorders, deliver patient counselling on medication use and adherence, and monitor adverse drug reactions. Medications prescribed may include topical corticosteroids (e.g., clobetasol propionate 0.05% gel\u002Fointment applied 2-3 times daily for 2-4 weeks, fluticasone propionate spray off-label), topical antifungals (e.g., nystatin oral suspension or miconazole oral gel), and other supportive therapies as per standard care. The intervention continues throughout the study period.",[13],"Behavioral: Pharmacist-Led Prescribing Optimization and Patient Counselling",{"label":15,"type":16,"description":17,"interventionNames":18},"Control Arm: Usual Dental Care","NO_INTERVENTION","Participants in this arm will receive routine dental care for oral mucosal disorders according to existing clinical practice. Prescriptions, counselling, and follow-up will be provided at the discretion of the treating dentist, without pharmacist-led prescription audit, structured feedback, standardized counselling, or formal adverse drug reaction monitoring as part of the study protocol.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"BEHAVIORAL","Pharmacist-Led Prescribing Optimization and Patient Counselling","This intervention involves a structured, pharmacist-led model integrated into routine dental care for patients with oral mucosal disorders. A clinical pharmacist will review dental prescriptions using standardized, evidence-based drug algorithms; provide audit and feedback to dentists; deliver structured patient counselling focused on correct medication use and adherence; and monitor for adverse drug reactions using validated tools. The intervention targets improvement in prescribing quality, medication safety, and patient outcomes, without introducing investigational drugs or altering standard treatment choices.",[9],[26,30,34],{"name":27,"affiliation":28,"role":29},"Tamer Hassan","Gulf Medical University","STUDY_CHAIR",{"name":31,"affiliation":32,"role":33},"Ramam Sripada","Sri Balaji Vidyapeeth University","STUDY_DIRECTOR",{"name":35,"affiliation":32,"role":36},"Nasma Pulikkalakath","PRINCIPAL_INVESTIGATOR",[38],{"name":39,"role":40,"phone":41,"phoneExt":18,"email":42},"Nabeel Ayappali Kalluvalappil","CONTACT","+97192023517","n.kalluvalappil@fu.ac.ae",{"type":36,"investigatorFullName":39,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Lecturer",[46],{"name":32,"class":47},"UNKNOWN","100648199","improving-prescribing-quality-for-oral-mucosal-disorders-using-a-pharmacist-led-model-100648199",false,"NCT07721090","Improving Prescribing Quality for Oral Mucosal Disorders Using a Pharmacist-Led Model","Pharmacological Management Optimization for Oral Mucosal Disorders: A Clinical Pharmacist Led Cluster Randomized Controlled Trial With Implementation Science Evaluation","Inclusion Criteria:\n\n* Adults aged 18 years and above\n* Diagnosed with an oral mucosal disorder (oral lichen planus, recurrent aphthous stomatitis, burning mouth syndrome, Herpes viral infection or oral candidiasis)\n* Attending participating dental clinic sessions during the study period\n* Prescribed pharmacological treatment for the oral mucosal condition\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Patients without a confirmed diagnosis of an oral mucosal disorder\n* Patients requiring immediate emergency care or hospitalization\n* Patients currently enrolled in another interventional clinical trial\n* Known hypersensitivity to commonly prescribed medications used in the study\n* Patients unable to comply with follow-up or study procedures","ALL","18 Years","70 Years",{"count":59,"type":60},336,"ESTIMATED","INTERVENTIONAL",[63],"NA","This study aims to improve how oral mucosal disorders-such as oral lichen planus, recurrent aphthous stomatitis, burning mouth syndrome, herpes viral infection and oral candidiasis-are treated in dental settings. A pharmacist will work with dentists to review prescriptions, provide feedback, counsel patients, and monitor medication safety. Dental clinics will be assigned to either the pharmacist-led model or usual care. The study will evaluate whether this approach improves prescribing quality, patient adherence, symptom control, and safety. The findings may help establish a more standardized, effective way to manage these common oral conditions in routine dental practice.",[66,67,68,69,70],"Oral Lichen Planus","Recurrent Aphthous Stomatitis","Burning Mouth Syndrome","Oral Candidiasis","Herpes Virus Infection",[72,66,67,68,69,73,74,75],"Oral Mucosal Diseases","Medication Therapy Management","Drug Prescriptions","Patient Compliance","NOT_YET_RECRUITING","2026-07-19",{"date":79,"type":80},"2026-07-22","ACTUAL",{"date":82,"type":60},"2026-07-01",{"date":84,"type":60},"2027-12-31",{"name":5,"class":6}]